1Schmid BC, Oehler MK.New perspectives in ovarian cancer treatment [J ].Maturitas, 2014,77:128-136.
2Cannistra SA.Cancer of the ovary [J].N Engl J Med, 2004,351: 2519-2529.
3Kalia M.Personalized oncology: recent advances and fiJture chal- lenges[J].Metabofism,2013,62(Suppl 1):S11-S14.
4Johnatty SE, Beesley J, Gao B, et al.ABCB1 (MDRI) polymor- phisms and ovarian cancer progression and survival: a compre- hensive analysis from the Ovarian Cancer Association Consor- tium and The Cancer Genome Atlas [J].Gynecol Oneol, 2013, 131:8-14.
5Vella N, Aiello M, Russo AE, et al.'Genetie profiling" and ovari- an cancer therapy (review) [J ].Mol Med Rep, 2011,4:771-777.
6Tewari KS, Sill MW, Long H J, et al.Improved survival with beva- cizumab in advanced cervical cancer [J].N Engl J Med, 2014, 370:734-743.
7Gyanchandani R, Sano D, Ortega AMV, et al.Interleukin-8 as a modulator of response to bevaeizumab in preclinical models of head and neck squamous cell carcinoma [J].Oral Oncol, 2013, 49:761-770.
8Suh DH, Kim JW, Kang S, et al.Major clinical seareh advances in gynecologic cancer in 2013 [J].J Gynecol Om'.ol, 2014, 25: 236-248.
9Schiavone MB, Bashir S, Herzog TJ.Biologic therapies aml per- sonalized medicine in gynecologic malignancies [J ].Obstet Gy- necol Clin North Am ,2012,39:131-144.
10Sood AK, Coleman RL.Targeted therapy in gynecologic oncolo- gy: biology, strategy, and assessment [J ] .Gynecol Oncol, 2010, 116:155-156.
